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Previous event rate ratio
PERR
Unmeasured confounding factors
Residual confoundingBackground: Adults 65 years and older (seniors) experience more complications following influenza
infection than younger adults. We estimated the relative vaccine effectiveness (rVE) of a trivalent high
dose (HD-IIV3) versus an adjuvanted trivalent influenza vaccine (aIIV3) in seniors for respiratory-
related hospitalizations.
Methods: We conducted a retrospective cohort study using claims data from Optum’s Clinformatics
Data Mart to compare outcome rates between seniors who received HD-IIV3 versus aIIV3 during the
2016/17 and 2017/18, predominantly A/H3N2 respiratory seasons. Rates were adjusted for demographic
characteristics, comorbid conditions, previous influenza vaccination, and geography. We used the previ-
ous event rate ratio (PERR) approach to address bias by time-fixed unmeasured confounders.
Results: We identified 842,282 HD-IIV3 and 34,157 aIIV3 recipients for the 2016/17 season and 1,058,638
HD-IIV3 and 189,636 aIIV3 recipients for the 2017/18 season. The pooled rVE of HD-IIV3 versus aIIV3 for
respiratory-related hospitalizations over both seasons was 12% (95% confidence interval: 3.3%–20%); 13%
(6.4% to 32%) for the 2016/17 season and 12% (2.1%–21%) for the 2017/18 season.
Conclusions: Pooled over two predominantly A/H3N2 respiratory seasons, HD-IIV3 was associated with
fewer respiratory hospital admissions than aIIV3 in senior members of large national managed health
care company in the U.S.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Background
Adults 65 years and older (hereinafter referred to as seniors) are
at greater risk for complications following influenza infection com-
pared with younger adults, due in part to immunosenescence and
increased comorbid conditions, leading to decreased vaccine effi-
cacy and increased severity of influenza-related complications[1,2]. As a result, influenza-associated hospitalization and mortal-
ity rates are significantly higher in this age group [3–6]. In the
2017–18 respiratory season, seniors in the United States (U.S.)
were estimated to have incurred over 650,000 influenza-
associated hospitalizations and 65,000 influenza-associated deaths
– 69% and 86% of the total number of influenza-associated hospi-
talizations and deaths, respectively [7]. Vaccination is the best pre-
ventive strategy against influenza infection [8]. As the U.S.
population continues to age, it has become vitally important to
use influenza vaccines that have demonstrated improved health
outcomes in this high-risk population.
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from egg-grown viruses and contain 15 mg of hemagglutinin (HA)
from each of three (trivalent, SD-IIV3, 45 mg HA total) or four
(quadrivalent, SD-IIV4, 60 mg HA total) strains and are licensed in
the U.S. for use in individuals 6 months of age or older. Due to
immunosenescence, there is a need for vaccines that provide better
protection than SD among seniors. Currently in the U.S., two influ-
enza vaccines are licensed exclusively for use in seniors: an egg-
grown trivalent inactivated high dose (HD-IIV3) influenza vaccine
(Fluzone High-Dose, Sanofi Pasteur) and an egg-grown trivalent
inactivated adjuvanted (aIIV3) influenza vaccine (Fluad, Seqirus).
HD-IIV3 aims to improve protection through quadrupling the dose
per influenza strain from 15 mg HA to 60 mg HA (180 mg total)
whereas aIIV3 is an SD-IIV3 vaccine to which an oil-in-water emul-
sion of squalene oil (MF59) is added.
In a randomized clinical trial (RCT), HD-IIV3 demonstrated
superior efficacy (pre-specified superiority criterion: lower limit
of the 2-sided 95% confidence interval (CI): >9.1%) in preventing
clinically-relevant influenza disease, compared to SD-IIV3 [9]. In
a meta-analysis of 7 studies that were conducted after licensure,
HD-IIV3 was associated with less influenza-like illness compared
to SD-IIV3 (rVE of 19.5%; 95% CI: 8.6–29.0%), with less hospitalized
pneumonia (rVE of 24.3%, 95% CI: 13.9–33.4%) and with less
hospitalizations for cardiorespiratory disease (rVE of 18.2%; 95%
CI: 6.8–28.1%) [10]. Individual studies conducted among various
populations during the 2011–12 through 2017–18 seasons have
reported HD-IIV3 to be associated with reduced influenza-related
complications compared to SD-IIV3 [11–18].
Although a few observational studies report that aIIV3 was
associated with reduced influenza-related complications in seniors
as compared to SD-IIV3 [18–20], no RCTs have evaluated the rela-
tive efficacy of aIIV3 against laboratory-confirmed influenza in
seniors [21]. A meta-analysis, which included 39 trials comparing
adults 60 years of age or older, who received either intradermal
IIV3, HD-IIV3, or aIIV3, reported that both HD-IIV3 and aIIV3
demonstrated a significantly higher post-vaccination geometric
mean titer to A(H3N2), as compared to SD-IIV3. Specifically, HD-
IIV3 induced 82% higher titers to A(H3N2) as compared to SD-
IIV3, which was statistically significantly higher than the 52%
higher titers induced by aIIV3. In addition, HD-IIV3 elicited higher
antibody titers in response to A(H1N1) and B/Victoria viruses, as
compared to SD-IIV3 [22].
The recent utilization of both HD-IIV3 and aIIV3 in the U.S.
enables the use of routinely collected data to assess the comparative
effectiveness of the two vaccines. Recently, the first such observa-
tional study (Izurieta et al., J Infect Dis, 2018) reported that
HD-IIV3 was associated with fewer influenza-related hospital
encounters than aIIV3 (rVE of 7.7%, 95% CI: 5.1%, 10.2%) [18]. This
study relied on exposure modelingmethods (propensity score) that
only adjust formeasured confounding variables, but cannot account
for unmeasured ones [23]. Frailty, for instance, is a confounder that
may influence choice of vaccine, but may be hard to capture using
claims data [15]. As such, there is a need for further comparative
effectiveness research using methods that, to some extent, can
address confounding by unmeasured variables. Here, we use the
previous event rate ratio (PERR) approach, which adjusts for mea-
sured and unmeasured time-fixed confounders, to provide further
evidence on the comparative effectiveness of HD-IIV3 versus aIIV3.2. Methods
2.1. Design and data sources
We conducted a retrospective cohort study using claims data
from Optum’s Clinformatics Data Mart (CDM) to compare out-come rates between recipients of HD-IIV3 and aIIV3 during two
respiratory seasons: 2016/17 and 2017/18.
CDM is derived from a database of administrative health claims
for members of a large national managed care company affiliated
with Optum (hereinafter referred to as members). The database
includes approximately 17–19 million annually covered members,
for a total of over 60 million unique members over a 9 year period
(1/2007 through 12/2018). CDM is statistically de-identified under
the Expert Determination method consistent with HIPAA [24,25].
The administrative claims submitted for payment by providers
and pharmacies are verified, adjudicated, adjusted, and de-
identified prior to inclusion. CDM data comprises both commercial
and Medicare Advantage health plan data. The population is geo-
graphically diverse, spanning all 50 states. In addition to medical
claims and pharmacy claims, the data includes information on
member eligibility and inpatient confinements.
2.2. Study population and influenza vaccination
The study population included all members aged 65 years and
older at time of vaccination. Vaccinations received in a doctor’s
office were identified by Current Procedural Terminology (CPT)
codes (HD-IIV3 vaccine CPT code: 90662, aIIV3 vaccine CPT code:
90653) or National Drug Code (NDC, Supplemental Table 2). Vacci-
nations received in a community pharmacy were identified by
brand names.
2.3. Study periods
Following prior work [26], we defined the start of the respira-
tory season as July 1 and the end as June 30 of the next calendar
year. Within each respiratory season, we defined a baseline period
starting on July 1 and ending on the day of vaccination. We used
this period as an indicator for confounding, because here the vac-
cines will have no impact on the outcome rates: a treatment effect
in this period could be an indicator for residual confounding [27].
Allowing for immunological response following vaccination, the
observation period started two weeks after vaccination and ended
at the end of the respiratory season on June 30. Here, outcome
rates may be influenced by the vaccines. Baseline characteristics
were observed during one year before vaccination.
2.4. Inclusion and exclusion criteria
To increase the probability of capturing a member’s baseline
characteristics and outcomes, we included members with continu-
ous enrollment starting at least one year before vaccination and
ending not before the end of the respiratory season on June 30. If
a member dies during this period, we counted their enrollment
until the month of death. We applied two exclusion criteria. First,
members for whom we found more than one vaccination record
per respiratory season were excluded. Second, members with an
observation period less than two weeks – due to late vaccination
or death – were excluded. We relaxed these inclusion and exclu-
sion criteria in a stability analysis [28].
2.5. Baseline characteristics
We classified members on demographic characteristics; month,
region and point of vaccination (community pharmacy versus doc-
tor’s office); influenza vaccination in the previous season; and by
presence of certain health conditions (Table 1). We captured base-
line characteristics during a period of one year before vaccination.
We identified the 17 medical conditions used to calculate the
Deyo-Charlson score by primary and secondary discharge diagno-
sis codes (International Classification of Diseases [ICD]-10) from
374 R. van Aalst et al. / Vaccine 38 (2020) 372–379outpatient visits and hospital admissions. We deemed a condition
present on the basis of a qualifying ICD code from a single hospital
admission or two outpatient visits.2.6. Outcomes
The primary outcome of the study was any hospitalization in
which the patient record indicated a respiratory condition (ICD-
10-CM: Jxx) as the principal discharge diagnosis [29]. The sec-
ondary outcome was any hospitalization for a cardio-respiratory
condition (ICD-10-CM: Ixx – Jxx). We report hospitalizations for
a urinary tract infection (UTI) as a test-negative control outcome
because we do not expect these to be preventable by either influ-
enza vaccine. Additionally, we explored stratification of primary
and secondary outcomes by more specific disease groups (e.g. hos-
pitalizations for pneumonia, Supplemental Tables 1, 5 and 6).2.7. Statistical analysis
We are interested in comparing the effectiveness of the HD-IIV3
and aIIV3 vaccines. Because we expected confounding by indica-
tion – resulting in treatment selection bias – by variables that
are either unmeasured or measured inaccurately (e.g. baseline
comorbidities), we employed the previous event rate ratio (PERR)
approach, which adjusts for measured and unmeasured, time-
fixed confounding factors [30–32]. This approach, a type of
difference-in-differences analysis [33], compares the outcome rate
change from baseline to observation period in the HD-IIV3 cohort
with the rate change in the aIIV3 cohort (Supplemental Fig. 1).
These rate changes can be rewritten as the change in the relative
risk from baseline ðRRbÞ to observation period ðRRoÞ, or ðRRoRRbÞ: aTable 1
Baseline characteristics of high dose (HD-IIV3) and adjuvanted influenza vaccine (aIIV3) r
Season 2016/17
HD-IIV3 aIIV3
Study Population 842,282 34,157
Gender
Male 351,264 42% 14,474
Female 490,969 58% 19,683
Unknown 49
Race
Asian 23,751 2.8% 1,000
African American 54,599 6.5% 1,896
Hispanic 61,328 7.3% 2,296
White 569,019 68% 23,351
Unknown Race 138,384 16% 5,728
Age
65–69 189,369 22% 8,096
70–74 234,809 28% 10,060
75–79 175,214 21% 7,116
80–84 125,263 15% 4,736
85+ 117,627 14% 4,149
Age (mean, sd) 75.57 6.67 75.14
HHS Region
Region 1: CT, ME, MA, NH, RI, VT 31,004 3.7% 3,437
Region 2: NJ, NY, PR, VI 62,302 7.4% 2,993
Region 3: DE, DC, MD, PA, VA, WV 27,988 3.3% 619
Region 4: AL, FL, GA, KY, MS, NC, SC, TN 210,553 25% 7,359
Region 5: IL, IN, MI, MN, OH, WI 165,564 20% 6,221
Region 6: AR, LA, NM, OK, TX 83,243 10% 3,193
Region 7: IA, KS, MO, NE 38,421 4.6% 1,177
Region 8: CO, MT, ND, SD, UT, WY 59,664 7.1% 3,159
Region 9: AZ, CA, GU, HI, NV 122,521 15% 3,773
Region 10, AK, ID, OR, WA 39,264 4.7% 2,151
Unknown Region 1,758 0.2% 75measure of the treatment effect adjusted for unmeasured time-
fixed confounding variables (variables that are constant during
the baseline and observation periods of a given respiratory season).
We selected the PERR method because its performance to reduce
bias caused by unmeasured confounding factors has been thor-
oughly described, both in simulation studies [30,32,34] and an
empirical study comparing PERR estimates with RCTs [35]. The
crude (unadjusted for measured baseline variables) relative vac-
cine effectiveness (rVE) is calculated as




We estimated crude rVEs by fitting a Poisson regression model
with an interaction term between two variables, the period (obser-
vation versus baseline) and thetreatment (HD-IIV3 versus aIIV3).
The regression model is shown below.
log E Yð Þð Þ ¼ seasonþ periodþ treatmentþseason periodþ season treatment þ period treatmentþseason period treatment þ logðdaysatriskÞ ð2Þ
The coefficient of the interaction term period treatment is
used to estimate RRoRRb
 
, and thus the crude rVE. We adjusted the
crude rVE for measured confounders by adding all baseline charac-
teristics of Table 1 as covariates to the model above (model 2,
except for Age Groups and the Deyo-Charlson Score, to prevent
collinearity with Age and individual comorbid conditions). Pooled
results over the two seasons were also calculated by removingecipients.
Season 2017/18
SMD* HD-IIV3 aIIV3 SMD*
1,058,638 189,636
42% 0.01 443,049 42% 79,031 42% 0.00
58% 0.01 615,545 58% 110,596 58% 0.00
44 9
2.9% 0.01 29,845 2.8% 4,801 2.5% 0.02
5.6% 0.04 75,833 7.2% 15,011 7.9% 0.03
6.7% 0.02 76,975 7.3% 11,645 6.1% 0.05
68% 0.02 689,639 65% 124,306 66% 0.01
17% 0.01 168,024 16% 30,818 16% 0.01
24% 0.03 233,431 22% 42,784 23% 0.01
29% 0.03 307,216 29% 57,242 30% 0.03
21% 0.00 227,916 22% 40,576 21% 0.00
14% 0.03 150,231 14% 25,772 14% 0.02
12% 0.05 139,844 13% 23,262 12% 0.03
6.49 0.07 75.46 6.71 75.22 6.61 0.04
10% 0.25 40,951 3.9% 8,004 4.2% 0.02
8.8% 0.05 72,956 6.9% 15,392 8.1% 0.05
1.8% 0.10 33,411 3.2% 4,737 2.5% 0.04
22% 0.08 251,396 24% 79,399 42% 0.39
18% 0.04 204,987 19% 26,293 14% 0.15
9.3% 0.02 118,510 11% 10,684 5.6% 0.20
3.4% 0.06 57,121 5.4% 4,040 2.1% 0.17
9.2% 0.08 74,882 7.1% 7,596 4.0% 0.13
11% 0.10 155,834 15% 22,016 12% 0.09
6.3% 0.07 46,356 4.4% 11,108 5.9% 0.07
0.2% 0.00 2,234 0.2% 367 0.2% 0.00
Table 1 (continued)
Season 2016/17 Season 2017/18
HD-IIV3 aIIV3 SMD* HD-IIV3 aIIV3 SMD*
Study Population 842,282 34,157 1,058,638 189,636
Month of Vaccination
August & September 298,370 35% 7,009 21% 0.34 354,103 33% 60,234 32% 0.04
October 335,082 40% 9,497 28% 0.26 437,160 41% 77,418 41% 0.01
November 130,471 15% 8,711 26% 0.25 160,983 15% 28,144 15% 0.01
December & January 68,463 8.1% 7,886 23% 0.42 91,407 8.6% 20,429 11% 0.07
Other 9,896 1.2% 1,054 3.1% 0.13 14,985 1.4% 3,411 1.8% 0.03
Time at risk
Baseline period (mean, sd) 107 33 129 41 0.58 108 35 110 39 0.05
Observation period (mean, sd) 242 35 221 42 0.56 241 37 239 40 0.04
Point of Vaccination
Community Pharmacy 413,339 49% 24,277 71% 0.46 513,661 49% 135,577 71% 0.48
Doctor’s office 440,955 52% 10,444 31% 0.45 564,019 53% 56,924 30% 0.49
Frailty Proxy
No hospitalization record found 743,299 88% 30,458 89% 0.03 930,074 88% 168,412 89% 0.03
All-cause hospitalizations (mean, sd) 0.19 0.64 0.17 0.60 0.03 0.19 0.66 0.17 0.61 0.03
Study Population 842,282 34,157 1,058,638 189,636
Comorbid Conditions
No record of comorbid conditions found 401,006 48% 17,782 52% 0.09 482,522 46% 90,969 48% 0.05
Myocardial Infarction 23,500 2.8% 864 2.5% 0.02 32,502 3.1% 5,284 2.8% 0.02
Congestive Heart Failure 60,669 7.2% 2,094 6.1% 0.04 84,497 8.0% 13,278 7.0% 0.04
Peripheral Vascular Disease 77,503 9.2% 2,721 8.0% 0.04 107,632 10% 17,441 9.2% 0.03
Cerebrovascular Disease 52,437 6.2% 1,981 5.8% 0.02 69,223 6.5% 11,869 6.3% 0.01
Dementia 25,859 3.1% 1,040 3.0% 0.00 34,905 3.3% 5,638 3.0% 0.02
Chronic Pulmonary Disease 107,899 13% 3,970 12% 0.04 146,273 14% 24,726 13% 0.02
Connective Tissue / Rheumatic Disease 22,506 2.7% 809 2.4% 0.02 29,583 2.8% 5,055 2.7% 0.01
Peptic Ulcer Disease 5,230 0.6% 178 0.5% 0.01 6,778 0.6% 1,207 0.6% 0.00
Mild Liver Disease 14,929 1.8% 581 1.7% 0.01 21,396 2.0% 3,732 2.0% 0.00
Diabetes without complications 193,794 23% 7,046 21% 0.06 258,211 24% 43,469 23% 0.03
Diabetes with complications 81,327 10% 2,786 8.2% 0.05 121,912 12% 19,301 10% 0.04
Paraplegia and Hemiplegia 3,958 0.5% 145 0.4% 0.01 5,738 0.5% 873 0.5% 0.01
Renal Disease 102,056 12% 3,437 10% 0.07 138,137 13% 22,069 12% 0.04
Cancer 76,567 9.1% 2,926 8.6% 0.02 96,641 9.1% 16,965 8.9% 0.01
Moderate or Severe Liver Disease 1,407 0.2% 54 0.2% 0.00 2,015 0.2% 327 0.2% 0.00
Metastatic Carcinoma 6,897 0.8% 248 0.7% 0.01 9,323 0.9% 1,468 0.8% 0.01
AIDS/HIV 579 0.1% 18 0.1% 0.01 891 0.1% 162 0.1% 0.00
Deyo-Charlson Score (mean, sd) 1.38 1.94 1.22 1.82 0.08 1.50 2.06 1.38 1.96 0.06
Vaccinated in previous season
No vaccination record found 155,647 18% 7,568 22% 0.09 221,972 21% 40,370 21% 0.01
HD-IIV3 501,035 59% 17,464 51% 0.17 655,102 62% 105,145 55% 0.13
aIIV3 19 0.0% 4 0.0% 0.01 17,423 1.6% 12,007 6.3% 0.24
SD-IIV3 110,739 13% 6,524 19% 0.16 79,540 7.5% 18,816 9.9% 0.09
SD-IIV4 73,769 8.8% 2,494 7.3% 0.05 82,138 7.8% 12,217 6.4% 0.05
Other vaccine 1,073 0.1% 103 0.3% 0.04 2,463 0.2% 1,081 0.6% 0.05
HD-IIV3: high dose, trivalent; aIIV3: adjuvanted, trivalent; SD-IIV3: standard dose, trivalent; SD-IIV4: standard dose, quadrivalent; Other vaccine: cell culture-based,
quadrivalent; recombinant, quadrivalent; live-attenuated, quadrivalent.
* Common characteristics between the HD-IIV3 and aIIV3 cohorts with an absolute standardized mean difference (SMD) of more than or equal to 0.10 suggests a
substantial difference between groups.
R. van Aalst et al. / Vaccine 38 (2020) 372–379 375the interaction term season period treatment. We used a robust
variance estimator for each rVE, and after exponentiation, the
delta-method to calculate 95% confidence intervals.
We compared baseline characteristics between HD-IIV3 and
aIIV3 recipients using standardized mean differences. We adopted
the rule that an absolute standardizedmean difference smaller than
0.1 suggests no substantial differencebetween the comparedgroups
[36].2.8. Stability analyses
Supplemental Tables 7–15 catalog the various additional analy-
ses we performed to evaluate the stability of our main results with
slightly different study design choices [28]. Given the fact that the
PERR method only adjusts for time-fixed unmeasured confounding
factors, and the likelihood of potential time (baseline to observation
period) dependent unmeasured confounders to be correlated with
geographic location, we compared results from our primary analy-
sis with results stratified by state, the smallest geographic area in
our data set (Supplemental Tables 7 and 8). In addition, we com-pared results from the primary analysis with a matched cohort on
state and both state and month of vaccination (Supplemental
Table 9), both crude and adjusted for baseline characteristics (Sup-
plemental Table 10). In addition to comparing the primary analysis
to the matched cohorts, we also ran a primary analysis where we
added state level characteristics (Supplemental Table 4) as covari-
ates to the Poisson regression: our attempt to reduce unmeasured
confounding factors that are potentially time (period) dependent
(Supplemental Table 10, Primary Analysis+). Because of the small
number of aIIV3 recipients in 2016–17, we limited all state level
adjustments, stratification and matching to the 2017–18 season.
Given the fact that the PERR method uses longitudinal data, we
evaluated if patient-level clustering influenced our main analyses
by repeating them using generalized estimating equation methods
with the independent (Supplemental Table 12) and autoregressive-
1 (Supplemental Table 13) working correlation structure. Given the
fact that Poisson regression assumes limited heterogeneity of the
study population, we evaluated if overdispersion in the outcome
data influenced our main analyses by fitting a negative binomial
regression (Supplemental Table 14). Because temporal differences
between vaccination date and peak of the circulating viral activity
376 R. van Aalst et al. / Vaccine 38 (2020) 372–379vary by geography, we evaluated if these differences were suffi-
ciently adjusted for in our main analyses by repeating them after
matching on vaccination month and region (Supplemental
Table 14) [37]. Possible heterogeneity of insurance plans (e.g., dif-
ferent co-pays) can influence a member’s choice of one vaccine
over the other. We evaluated if heterogeneity of insurance plans
influenced our main analyses by adjusting for the 83 most common
insurance plans: the most granular stratification with at least one
member in each stratum during the two seasons (Supplemental
Table 14). In the last stability analysis, we assessed the effects of
relaxing the inclusion and exclusion criteria on the main results.
Because we required continuous enrollment until the end of the
observation period or death, whichever came first, we evaluated
if dropping this complete case requirement influenced our main
analysis. Instead, we required enrollment only to last until the start
of the observation period with a minimum length of the observa-
tion period of one day (instead of 14 days). Missing outcome data
– lost to follow-up – was addressed weighting complete cases with
the inverse of a member’s propensity of having a complete case,
using the baseline characteristics of Table 1 and insurance plan
type of all cases – complete and incomplete. In addition we only
counted the first hospitalization. We censored person-time after
the first hospitalization, death, or the end of the observation per-
iod, whichever occurred first (Supplemental Table 15).
3. Results
We identified 842,282 HD-IIV3 and 34,157 aIIV3 recipients for
the 2016/17 season and 1,058,638 HD-IIV3 and 189,636 aIIV3
recipients for the 2017/18 season. Table 1 lists all baseline charac-
teristics. Gender, race, age groups, number of all-cause hospitaliza-
tions and comorbid conditions were not substantially different
(absolute SMD less than to 0.1) between HD-IIV3 and aIIV3 recip-
ients. We did however observe substantial differences (absolute
SMD greater than, or equal to 0.1) in a number of baseline charac-
teristics. Some substantial differences were only observed in one
season: these were in geographic region and month of vaccination.
In 2016/17, Region 1 (Connecticut, Maine, Massachusetts, New
Hampshire, Rhode Island and Maine) received substantially more
aIIV3 vaccinations than HD-IIV3 vaccinations, while in 2017/18
the biggest difference was observed in Region 4 (Alabama, Florida,
Georgia, Kentucky, Mississippi, North and South Carolina and Ten-
nessee). In 2016/17, aIIV3 recipients received their vaccine, on
average, 3 weeks later than HD-IIV3 recipients, but we didn’t
observe a difference in 2017/18.Table 2
Crude rates, rate ratios (RR) and relative vaccine effectiveness (rVE) with 95% confidence in
for respiratory seasons 2016–17 and 2017–18.
Baseline period
Outcome No Rate RR
Season 2016-17
Respiratory disease aIIV3 121 101 (81, 120)
HD 3,193 129 (84, 185) 1.29 (1.03, 1.54)
Cardio-respiratory disease aIIV3 482 400 (359, 441)
HD 12,361 500 (402, 609) 1.25 (1.12, 1.38)
Urinary Tract Infection aIIV3 70 58 (43, 73)
HD 1,610 65 (35, 104) 1.12 (0.82, 1.42)
Season 2017-18
Respiratory disease aIIV3 622 109 (99, 119)
HD 4,390 140 (115, 167) 1.28 (1.16, 1.41)
Cardio-respiratory disease aIIV3 2,572 451 (431, 471)
HD 16,639 531 (483, 581) 1.18 (1.12, 1.23)
Urinary Tract Infection aIIV3 332 58 (51, 65)
HD 2,036 65 (50, 82) 1.12 (0.97, 1.26)
Rates are in number of outcomes (No) per 10,000 person-years. Hospitalizations were cla
using a robust variance estimator. We applied the Previous Event Rate Ratio (PERR)
(observation versus baseline period) and treatment (HD-IIV3 versus aIIV3).Other baseline characteristics were substantially different in
both seasons: the point of vaccination and the vaccination history.
We observed that 52% of HD-IIV3 recipients received their vaccine
in a doctor’s office, compared to 30% of aIIV3 recipients. In 2017/18,
62% of all HD-IIV3 recipients received HD-IIV3 in the previous sea-
son compared to 55% of all aIIV3 recipients. 6.3% of all aIIV3 recip-
ients had received aIIV3 in the previous season compared to 1.6% of
all HD-IIV3 recipients.
All imbalances in baseline characteristics were addressed by
including the variables of Table 1 as covariates in the adjusted
regression analysis.
During the baseline period, we observed statistically significant
higher hospitalization rates for respiratory disease among mem-
bers who would eventually receive HD-IIV3 (Table 2). Crude rate
ratios (HD-IIV3 versus aIIV3) were 1.29 (95% CI: 1.03, 1.54) and
1.28 (95% CI: 1.16, 1.42) for the 2016/17 and 2017/18 seasons,
respectively. During the observation period, however, the differ-
ence was less pronounced: 1.09 (95% CI: 0.68, 1.61) and 1.15
(0.93, 1.39) for the 2016/17 and 2017/18 seasons, respectively,
resulting in a crude rVE of HD-IIV3 versus aIIV3 of 15% (95% CI:
4.3%, 34%) in 2016/17 and 11% (95% CI: 1.0%, 20%) in 2017/18.
After adjusting the respiratory hospitalization rates for baseline
characteristics listed in Table 1, adjusted rate ratios (HD-IIV3 ver-
sus aIIV3) during the baseline period were 1.13 (95% CI: 0.91, 1.35)
and 1.14 (95% CI: 1.03, 1.25) for the 2016/17 and 2017/18 seasons,
respectively (Table 3), suggesting residual bias caused by unmea-
sured confounding factors. During the observation period the
adjusted rates were 0.98 (95% CI: 0.61, 1.44) and 1.01 (0.81, 1.22)
for the 2016/17 and 2017/18 seasons, respectively. We estimated
an adjusted rVE of HD-IIV3 versus aIIV3 of 13% (95% CI: 6.4%,
32%) in 2016/17 and 12% (95% CI: 2.1%, 21%) in 2017/18 (Supple-
mental Fig. 1). Pooling the data from both season resulted in an
adjusted summary rVE of 12% (3.3, 20%), Table 4.
For our secondary outcome, hospitalizations for cardio-
respiratory disease, the crude rVE of HD-IIV3 versus aIIV3 was
14% (95% CI: 4.0%, 25%) in 2016/17 and 5% (95% CI: 0.1%, 10%)
in 2017/18. After adjusting these hospitalization rates for baseline
characteristics listed in Table 1, the adjusted rVE was 13% (95% CI:
2.3%, 23%) in 2016/17 and 6% (95% CI: 0.6%, 11%) in 2017/18. Pool-
ing the data from both seasons resulted in an adjusted summary
rVE of 7% (2.3, 12%). For our test-negative control, hospitalizations
for UTI, the adjusted rVE was 20% (95% CI: 95%, 18%) in 2016/17
and 3% (95% CI: 12%, 17%) in 2017/18. Pooling the data from both
season resulted in an adjusted summary rVE of 1% (15, 13%),
suggesting no treatment effect.tervals for aIIV3 and HD-IIV3 (HD) recipients in the baseline and observation periods
Observation period
No Rate RR rVE*
513 248 (156, 362)
15,169 272 (106, 581) 1.09 (0.68, 1.61) 15% (4.3%, 34%)
1,584 767 (605, 947)
45,738 819 (508, 1255) 1.07 (0.84, 1.32) 14% (4.0%, 25%)
144 70 (35, 115)
5,042 90 (23, 250) 1.29 (0.65, 2.16) 16% (53%, 22%)
3,293 265 (217, 318)
21,260 304 (201, 443) 1.15 (0.93, 1.39) 11% (1.0%, 20%)
9,918 797 (723, 876)
62,269 891 (726, 1083) 1.12 (1.00, 1.24) 5% (0.1%, 10%)
1,064 86 (65, 109)
6,558 94 (53, 154) 1.10 (0.82, 1.42) 1.8% (13%, 16%)
ssified using the principal discharge diagnosis. Confidence intervals were calculated
to address unmeasured confounders by including an interaction term of Period
Table 3
Rate ratios (RR) and relative vaccine effectiveness (rVE) with 95% confidence intervals for aIIV3 and HD-IIV3 recipients in the baseline and observation periods for respiratory
seasons 2016–17 and 2017–18, crude and adjusted for baseline characteristics.
Baseline period Observation period
Hospitalizations RR, crude RR, adjusted RR, crude RR, adjusted rVE*, crude rVE*, adjusted
Season 2016–17
Respiratory disease 1.29 (1.03, 1.54) 1.13 (0.91, 1.35) 1.09 (0.68, 1.61) 0.98 (0.61, 1.44) 15% (4.3%, 34%) 13% (6.4%, 32%)
Cardio-respiratory disease 1.25 (1.12, 1.38) 1.11 (1.00, 1.23) 1.07 (0.84, 1.32) 0.97 (0.77, 1.20) 14% (4.0%, 25%) 13% (2.3%, 23%)
Urinary Tract Infection 1.12 (0.82, 1.42) 0.98 (0.72, 1.24) 1.29 (0.65, 2.16) 1.17 (0.59, 1.96) 16% (53%, 22%) 20% (59%, 19%)
Season 2017–18
Respiratory disease 1.28 (1.16, 1.41) 1.14 (1.03, 1.25) 1.15 (0.93, 1.39) 1.01 (0.81, 1.22) 11% (1.0%, 20%) 12% (2.1%, 21%)
Cardio-respiratory disease 1.18 (1.12, 1.23) 1.07 (1.02, 1.12) 1.12 (1.00, 1.24) 1.01 (0.91, 1.11) 5% (0.1%, 10%) 6% (0.6%, 11%)
Urinary Tract Infection 1.12 (0.97, 1.26) 1.01 (0.88, 1.14) 1.10 (0.82, 1.42) 0.99 (0.73, 1.28) 1.8% (13%, 16%) 2.5% (12%, 17%)
Rates are in number of outcomes (No) per 10,000 person-years. Hospitalizations were classified using the principal discharge diagnosis. Confidence intervals were calculated
using a robust variance estimator. We applied the Previous Event Rate Ratio (PERR) to address unmeasured confounders by including an interaction term of Period
(observation versus baseline period) and treatment (HD-IIV3 versus aIIV3). The Rate rations and PERR were adjusted for observed confounding factors by including all the
baseline characteristics of Table 1 as covariates, except for Age Groups and the Deyo-Charlson Score, to prevent collinearity with Age and individual comorbid conditions.
Hospitalizations were classified using the principal discharge diagnosis.
Table 4
Relative vaccine effectiveness (rVE) with 95% confidence intervals of high dose (HD-IIV3) versus adjuvanted influenza vaccine (aIIV3) for respiratory






Respiratory disease 13% (6.3%, 32%) 12% (2.1%, 21%) 12% (3.3%, 20%)
Cardio-respiratory disease 13% (2.3%, 23%) 6% (0.6%, 11%) 7.0% (2.3%, 12%)
Urinary Tract Infection 20% (59%, 19%) 2.5% (12%, 17%) 0.7% (14%, 13%)
Confidence intervals were calculated using a robust variance estimator. We applied the Previous Event Rate Ratio (PERR) to address unmeasured
confounders by including an interaction term of Period (observation versus baseline period) and treatment (HD-IIV3 versus aIIV3). The PERR was
adjusted for observed confounding factors by including all the baseline characteristics of Table 1 as covariates, except for Age Groups and the
Deyo-Charlson Score, to prevent collinearity with Age and individual comorbid conditions. Hospitalizations were classified using the principal
discharge diagnosis.
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We observed low numbers of hospitalizations for respiratory
disease for the 2017–18 season when stratified by state, limiting
the conclusions than can be drawn from these results (Supplemen-
tal Tables 7 and 8). Two matched cohort analyses for the 2017–18
season: one on state only, and another on both state and month of
vaccination, resulted in higher rVEs compared to the primary anal-
ysis of season 2017–18 (Supplemental Tables 9 and 10). The higher
rVEs were mainly driven by higher rate ratios in the baseline per-
iod, suggesting increased residual confounding. Pooled results
from the matched analysis over two seasons on vaccination month
and region to adjust for temporal and geographic heterogeneity
were similar to the results of the main analysis (Supplemental
Table 14). Results of a stability analysis where we added state level
characteristics as covariates to the Poisson regression of the pri-
mary analysis, as well as all other stability analyses, were similar
to the results of the main analysis (Supplemental Tables 11–13
and 15).4. Discussion
We analyzed 1,900,920 HD-IIV3 and 223,793 aIIV3 recipients
aged 65 years and older in senior members of large national man-
aged care company in the U.S. Pooled over two seasons, HD-IIV3
was associated with lower hospitalization rates for respiratory as
well as cardio-respiratory disease compared to aIIV3. More specif-
ically, the adjusted rVE of HD-IIV3 versus aIIV3 for hospitalizations
with underlying respiratory disease was 12% (95% CI: 3.3, 20%). The
adjusted rVE of HD-IIV3 versus aIIV3 for hospitalizations with
underlying cardio-respiratory disease was 7% (95% CI: 2.3, 12%).Our findings are consistent with data from the U.S. Centers for
Disease Control and Prevention. Indeed, Izurieta and colleagues
reported that HD-IIV3 was associated with lower hospitalization
rates for probable influenza (hospitalization with an administra-
tive ICD-10 code of 489 on any position on the claim) when com-
pared to aIIV3, with an rVE of 7.7%, (95% CI: 5.1%, 10.2%) in the
2017–18 season [18]. Similarly, we also estimated that HD-IIV3
was associated with reduced hospitalizations for respiratory dis-
ease. Of note, our outcome definition was different than Izurieta
et al. in that it captured, in our primary analysis, all respiratory
related hospital admissions during the influenza season. The speci-
ficity and sensitivity of our outcome and the one reported by Izuri-
eta are therefore different. Further, Izurieta at al. used an inverse
probability of treatment weighting (IPTW) method to balance dif-
ferences between cohorts. However, propensity score methods
adjust only for measured confounders, not unmeasured con-
founders. If HD-IIV3 recipients were frailer than aIIV3 recipients,
residual confounding from unmeasured variables would bias the
relative treatment effect to the null. For these two reasons, it is
challenging to quantitatively compare the rVEs between our study
and Izurieta et al; however, it is noteworthy that directionally HD-
IIV3 is in both studies associated with reduced hospitalization
rates compared to aIIV3.
Our study has multiple strengths. First, we used a method that
adjusts for confounding from unmeasured variables through the
use of the PERR method and measured variables through regres-
sion. The adjusted rate ratios in the baseline period (Table 3) sug-
gest residual bias caused by unmeasured confounding factors [27].
Because of this observation, we feel it appropriate to use the PERR
method. When comparing the effectiveness of IIV3-HD and IIV3-SD
in the VHA population using the PERR method, Young-Xu and col-
leagues observed a similar pattern: the relative risk in the observa-
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IIV3-HD [15]. The relative risk in the baseline period, however, was
1.54 suggesting a strong selection bias. Applying PERR resulted in a
relative risk of 0.75 – more in line with a wide body of evidence
consisting of both randomized and observational studies [10]. It
might be helpful to keep in mind that PERR is in essence a form
of difference-in-differences – a method widely used in the field
of economics to adjust for unmeasured confounding factors [33].
Second, we included in our study a negative control outcome of
UTI admissions where we expected no association between vacci-
nation status and the outcome. Reassuringly we did not observe a
treatment effect UTI in season 2017–18 and the pooled analysis.
This allows us to assume that the PERR model was not misspeci-
fied. Third, by requiring an observation period of at least two
weeks we created a minimal time window to observe outcomes.
As a result, we excluded members with a high propensity of dying
at time of vaccination, a confounding variable that is otherwise
hard to measure [38], and members who received vaccination after
June 16. Because we realize that any time subjects are excluded
from an analysis, other biases might be introduced inadvertently,
we dropped this requirement in a stability analysis. Last, we exten-
sively tested the validity of our assumptions and design choices by
including various stability analyses, which did not alter our find-
ings in a clinically significant way (Supplemental Tables 7–15).
Our study also has limitations. First, the heterogeneity in influ-
enza viral circulation and intensity from year to year limits the
generalizability of the study results as the two seasons of our study
where predominantly H3N2 with limited H1N1 or B circulation. In
2016–17, public health laboratories typed 76% of all positive influ-
enza tests to be of H3N2, 2% were H1N1, and 22% were type B [39].
In 2017–18, the distribution was 60% H3N2, 11% H1N1, and 29%
type B [2]. Additionally, because our study aIIV3 cohort in 2016–
17 was over fivefold smaller than in 2017–18, our combined
results were heavily influenced by the second season, in which a
recent study demonstrated reduced protection from antibodies
induced by vaccination to egg-propagated A/H3N2 compared with
antibodies to the circulating a/H3N2 virus [40]. The impact on the
current analysis, if any, is unclear because both HD-IIV3 and aIIV3
are egg-based vaccines. Of note, the 2016–17 season was charac-
terized by a good match between circulating strains and vaccine
antigens. The rVE for respiratory-related hospitalizations did not
significantly decrease from season 2016–17 to season 2017–18. A
possible explanation could be that egg-adaptation reduces overall
vaccine effectiveness equally in both HD-IIV3 and in aIIV3. Second,
although PERR is an adaptation of the well-established difference-
in-differences method, it is unable to adjust for unobserved
time-varying (from baseline to observation period) confounders.
In addition, it assumes that outcome rate changes from baseline
to observation period in the aIIV3 cohort are similar to those in
the HD-IIV3 cohort, if they had received aIIV3 instead. This com-
mon ratio assumption is comparable with the parallel trend
assumption of the difference-in-differences method [33]. Although
this assumption cannot be tested, baseline and observation periods
are relatively close together, which reduces the chance of violating
this assumption for confounding factors like frailty, hospital/
provider access issues and propensity to hospitalize. PERR cannot
adjust for confounding factors that vary from baseline to observa-
tion period, like local influenza vaccination rates (impacting herd
immunity), and local prevalence of influenza – if left unmeasured.
In a stability analysis, we did measure these local confounding
factors – the length of the peak influenza season and influenza
vaccination rates in the general population – on the state level
for season 2017–18 (Supplemental Table 4), the most geographi-
cally granular data available to us. When adding these confounding
factors to the covariates of the primary analysis (Supplemental
Table 10), we saw a slightly higher rVE for hospitalizations forrespiratory disease in 2017–18: from 12% (95% CI: 2.1%, 21%) to
14% (95% CI: 3.4%, 24%). Matching on state resulted in even higher
rVEs, but mainly driven by higher rate ratios in the baseline period,
suggesting increased residual confounding (Supplemental
Table 10). Our data did not allow for capturing of geographic
heterogeneity of potentially time-varying confounding factors on
a more granular level than the state level. Potential variation of
weather, viral activity and vaccination rates within a state (e.g.,
at the county or postal code level) may confound our results. We
could have further reduced confounding by indication had we
excluded providers offering both vaccines at the same location at
the same time. Although provider level details prevented us from
excluding these providers, doing so might have come at the cost
of increasing geographic heterogeneity of other confounding fac-
tors: when comparing HD-IIV3 with SD-IIV3, Izurieta and col-
leagues matched on provider to reduce this type of confounding
[41].
Third, the size of the cohort in 2016–17 did not enable us to
extract statistically significant inferences specific to that season.
Notably, the rVE for respiratory-related hospitalization in that first
season was 13% (95% CI: 6.4%, 32%) and the rVE against our neg-
ative control, where we estimated the rVE against UTI, was erratic
and non-statistically significant.
As the use of the HD-IIV3 and aIIV3 grows, future effectiveness
studies should attempt to examine more specific outcomes such as
hospital admissions with a principal discharge code for pneumo-
nia/influenza and hospital admissions following a positive influ-
enza test. Our study was not able to study the former due to
small cohort size and low incidence rates, and the latter due to
absence of laboratory results data. However, these specific end-
points will take public health closer to understanding the causal
link between these vaccines and preventing adverse health out-
comes following an influenza infection.5. Conclusion
Pooled over two predominantly A/H3N2 respiratory seasons,
HD-IIV3 was associated with fewer respiratory- and cardio-
respiratory-related hospital admissions than aIIV3 in senior mem-
bers of large national managed care company in the U.S.Funding statement
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